We are a research-driven pharmaceutical company with a singular focus: developing medicines that meaningfully improve and extend human life.
Medicrown Pharma was founded on a conviction that the boundaries of medicine are not fixed — they are waiting to be expanded by scientists who refuse to accept that good enough is good enough.
Our mission is to discover, develop, and deliver transformative medicines that address unmet medical needs across oncology, cardiology, neurology, infectious disease, rare disease, and vaccine prevention.
We operate with deep respect for patients, scientific rigour, ethical integrity, and a commitment to making our medicines accessible wherever they are needed most.
We let data lead. Every claim we make is backed by reproducible evidence and transparent methodology.
Patients are not abstractions. We work alongside patient communities to design trials and programmes that serve real lives.
We structure our access programmes so that geography and income are not barriers to life-saving treatment.
Comfort is the enemy of progress. We invest 18% of revenue into R&D and actively seek to disrupt our own best products.
Dr Emmanuel Chukwuemeka Ugwu founded the company after thorough scientific research and seed grant from family and friends.
CardioShield-1, our first-generation lipid-lowering agent, receives FDA approval after a landmark 7,000-patient trial.
Veridian lists on the NYSE raising $680M, funding expansion into Asia-Pacific and Sub-Saharan Africa.
Acquisition of NovaCyte Oncology seeds what would become the Veritacel™ portfolio — now one of our core growth pillars.
Launch of our Orphan Therapeutics unit, winning 6 orphan drug designations in its first three years of operation.
Our flagship 48,000 m² research campus opens in Singapore, consolidating AI-driven drug discovery capabilities.
Rapid pivot to mRNA vaccine technology results in a pandemic-response vaccine candidate in under 9 months.
Veridian medicines reach a cumulative 2.4 billion patient treatments globally, a milestone celebrated across all 38 offices.
Background in Veternary Medicine and with 26+ years in drug discovery and business.
Led development of 14 approved drug candidates. Former WHO Senior Advisor on Infectious Disease.
20 years in biopharma finance. Architected Veridian's three major acquisitions and the 2024 bond issuance.
Oversaw 200+ clinical trials. Board-certified internist and global advocate for equitable drug access.